Bevacizumab, a monoclonal antibody targeting VEGF, has shown moderate success in clinical trials against ovarian cancer [44,45] and it has been approved in Europe against advanced or recurrent in this disease in combination with other chemotherapy medicines [46]. This evidence concerns the gene VEGFA and ovarian cancer.